NewTradingView.com – Investing and Stock News
Investing and Stock News
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Investing

Brazil’s Copasa privatization path sharpens as Bradesco BBI reaffirms neutral rating

by December 3, 2025
written by December 3, 2025

Bradesco BBI reaffirmed its neutral recommendation for shares of Copasa (CSMG3), as the Minas Gerais-based sanitation company has a share price target of R$56.

According to local media outlet InfoMoney, the valuation translates to a 35% rise from the stock’s closing price in November. Already up around 100% year-to-date, Copasa’s shares have been bolstered by rising privatization hopes.

The government of Minas Gerais has taken key moves towards a sale, which is projected to take place in 1Q 2026.

ARSAE’s regulatory changes, both implemented and expected, strengthen the investment case regardless of the exact timing of privatization.

In this context, the bank revised its estimates based on a 99% probability for the privatization of Copasa.

BBI anticipates strong operational enhancement in private ownership, supported by simplified cost bases and annual capex, which would flow back to the RAB regularly, similar to São Paulo’s Sabesp.

EBITDA and earnings growth under privatization assumptions

Assuming Copasa goes private, BBI predicts a compound annual growth rate (CAGR) of 17% for EBITDA and 16% for EPS between 2025 and 2030.

These forecasts are based on lower operational expenses and increased profitability as investments translate into regulated revenue sources.

With efficiency gains becoming crucial to the value argument, the bank believes Copasa is poised to significantly increase its earnings capacity in the second part of the decade.

Dividend possibilities are also improving under this forecast. Copasa is not expected to suffer bylaw limits on distributions, allowing BBI to maintain a consistent 75% yearly distribution.

Dividend yields could be around 7% in fiscal year 2026, rising to over 8% in 2027, 11% in 2028, and more than 12% from 2029 onward.

Despite the neutral rating, BBI believes that growing yields provide an appealing buffer for income-focused investors.

Valuation scenarios: from R$80 to R$32

BBI’s basic scenario assumes a target price of R$56 per share. However, the bank proposes two possible paths based on political and regulatory results.

In an optimistic scenario, a privatized Copasa may achieve R$80 per share by the end of 2026, representing a 92% increase.

This value implies the corporation achieves a deeper operating expense reduction of roughly 50% and benefits from a compression of the IRR or discount rate to 8.5%, which is only 100 basis points more than the real yield of NTN-B bonds.

These advantages would be boosted by higher dividend yields.

In a pessimistic scenario, in which privatization is cancelled or postponed, and Copasa remains state-controlled, the fair value falls to approximately R$32 per share, representing a 24% devaluation.

BBI observes that the drop in NPV is mitigated by regulatory actions that are likely to be confirmed soon and implemented regardless of ownership, particularly the yearly capex and RAB update.

Despite emphasizing the risk, the bank believes this scenario is unlikely given the recent political momentum.

Why Minas Gerais is accelerating the sale

The financial pressures confronting Minas Gerais are a main reason, according to gas analysts at BBI, for the state’s sense of urgency.

For decades, Minas Gerais has been mired in acute fiscal crises, including a R$150 billion debt to the federal government.

Negotiations, which continue, aim to lighten this load by means of concessions such as smaller interest rates and part of the payment made with national property.

While Copasa itself is not one of the assets flagged for federal transfer, the state still needs a significant amount to meet investment commitments related to the debt pact.

Minas Gerais, to meet these commitments, is offering to sell most of its 50.1% stake in Copasa, probably keeping 10%-15%, with 10%-vote rights.

BBI states these measures are key to restoring state accounts and help stabilize the accounts of the state.

In fact, recent legislative moves further point to the determination of the government.

Copasa’s privatization bill initially required a popular referendum before lawmakers could vote; this constitutional requirement was successfully negotiated out by Minas Gerais.

By skipping this step, there is less political blowback, which clears a huge obstacle to the proposed sale in 2026.

Key steps ahead: concessions, fees, and regulatory alignment

Before the privatization can be finalized, several milestones remain.

Copasa must secure approval from the State’s Court of Auditors for Transparency of Tax Credits (TCE) and negotiate a new concession contract with Belo Horizonte, which accounts for one-third of the company’s revenue.

The contract is expected to extend the city’s concession from 2034 to 2073 and may require Copasa to pay a fee estimated between R$1 billion and R$1.5 billion, which would likely be added to the RAB.

The other 636 municipalities served by Copasa typically follow Belo Horizonte’s lead and are unlikely to demand substantial additional concession fees due to their limited bargaining power.

While the updated BH contract is expected to incorporate improved regulatory provisions, BBI notes that the framework may not reach the same breadth as that seen with Sabesp.

Several milestones must be met before the privatization can be finalized.

Copasa must obtain clearance from the State Court of Auditors for Transparency of Tax Credits (TCE) and negotiate a new concession contract with Belo Horizonte, which generates one-third of the company’s revenue.

The contract is planned to extend the city’s concession from 2034 to 2073, and Copasa may be required to pay a price ranging from R$1 billion to R$1.5 billion, which will most likely be added to RAB.

The post Brazil’s Copasa privatization path sharpens as Bradesco BBI reaffirms neutral rating appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Why Nvidia stock is bucking the general trend today
next post
Will Tesla stock outperform AI darlings like Nvidia and AMD if FSD goes mainstream?

You may also like

Why US sanctioned former EU official, 4 others;...

December 25, 2025

GLP-1 weight-loss pills set to reshape US food...

December 25, 2025

US stocks hold steady on Christmas Eve as...

December 25, 2025

Agios Pharma jumps 15% as FDA expands use...

December 25, 2025

Nvidia stock plunges after Intel’s 18A move: what...

December 25, 2025

Commodity wrap: gold, silver prices ease on Christmas...

December 25, 2025

Europe bulletin: FTSE slips, US-EU clash escalates, Secure...

December 25, 2025

Wall Street close: S&P 500 ends at record...

December 25, 2025

Evening digest: Bitcoin drifts as S&P 500 hits...

December 25, 2025

Tesla finds stability in energy as Rivian tests...

December 25, 2025
Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!




    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular Posts

    • 1

      Gold and Silver: Gold remains stable in the $2420 zone

    • 2

      Oil and natural gas: Oil is back on the positive side

    • 3

      The dollar index continues to pull back to a new low

    • 4

      IonQ Stock Review: Should You Consider Investing Now?

    • 5

      Gold Price Surge Hits $3,385 Amid Trade Tensions

    Recent Posts

    • North Korea releases images of development of nuclear-powered submarine

      December 25, 2025
    • Why US sanctioned former EU official, 4 others; what it says about transatlantic tech rift

      December 25, 2025
    • GLP-1 weight-loss pills set to reshape US food demand in 2026

      December 25, 2025
    • US stocks hold steady on Christmas Eve as investors watch Santa Claus rally

      December 25, 2025
    • Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat

      December 25, 2025

    Categories

    • Economy (20)
    • Editor's Pick (331)
    • Investing (134)
    • Stock (20)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: NewTradingView.com, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 NewTradingView.com All Rights Reserved.


    Back To Top
    NewTradingView.com – Investing and Stock News
    • Investing
    • Stock
    • Economy
    • Editor’s Pick